Donor immune cells aim to fight virus in vulnerable patients
NCT ID NCT03425526
First seen Feb 21, 2026 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This early-stage trial tests whether specially grown donor T cells can safely treat adenovirus infections in people with weakened immune systems, such as cancer patients. The cells are designed to target and kill the virus. The study will check for side effects and see if the infection improves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOCOMPROMISED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor T cells (adenovirus-specific cytotoxic T lymphocytes)
What this could lead to
If it works, this could offer a treatment option for dangerous adenovirus infections in people with weakened immune systems.
What could go wrong
This is a very early phase 1 trial with only 16 participants, so it may not work or could cause side effects. The cells are from donors, which carries risks like rejection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.